AEG-33773(AEG-33773) - 药物靶点：HSP90_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

HSP90

作用机制

HSP90 刺激剂(Heat shock 90kDa proteins stimulants)

治疗领域

神经系统疾病内分泌与代谢疾病

在研适应症-

非在研适应症

慢性疼痛糖尿病周围神经病变

原研机构

Aegera Therapeutics, Inc.

在研机构-

非在研机构

Aegera Therapeutics, Inc.

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 AEG-33773 相关的临床试验

EUCTR2009-011254-18-BG / Not yet recruitingN/A

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus Placebo in Patients with Painful Diabetic Peripheral Neuropathy - n/a

开始日期2009-10-02

申办/合作机构

Aegera Therapeutics, Inc.

NCT00891683 / Completed临床2期

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy

Two Phase 1 studies have been conducted with AEG33773 and available safety and tolerability data from these studies support further clinical development of AEG33773. The current study is proposed as a proof-of-concept study to assess the potential analgesic efficacy of AEG33773 to reduce pain associated with chronic Diabetic Peripheral Neuropathy.

开始日期2009-03-01

申办/合作机构

Aegera Therapeutics, Inc.

100 项与 AEG-33773 相关的临床结果

登录后查看更多信息

100 项与 AEG-33773 相关的转化医学

登录后查看更多信息

100 项与 AEG-33773 相关的专利（医药）

登录后查看更多信息

1

项与 AEG-33773 相关的文献（医药）

2010-05-01·IDrugs : the investigational drugs journal

American Society for Clinical Pharmacology and Therapeutics (ASCPT)-111th annual meeting. 17-20 March 2010, Atlanta, GA, USA.

作者: Veryard, Claire

The 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, held in Atlanta, included topics covering disclosures of new data in the field of pharmacokinetics and drug interactions. This conference report highlights selected presentations on pharmacokinetic studies of several investigational drugs, including evatanepag (Pfizer Inc), AEG-33773 (Aegera Therapeutics Inc), JNJ-16269110 (Johnson & Johnson Pharmaceutical Research & Development LLC), PF-3716539 (ViiV Healthcare), MK-0736 (Merck & Co Inc), a combination of Ginkgo biloba and cilostazol (Renexin SK Chemicals Co Ltd), PP-101 (Pacific Pharmaceuticals Co Ltd), ACT-178882 (Acetlion Ltd/Merck & Co Inc) and edoxaban (Daiichi Sankyo Co Ltd).

100 项与 AEG-33773 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性疼痛	临床2期	罗马尼亚	Aegera Therapeutics, Inc.	2009-03-01
慢性疼痛	临床2期	加拿大	Aegera Therapeutics, Inc.	2009-03-01
慢性疼痛	临床2期	美国	Aegera Therapeutics, Inc.	2009-03-01
慢性疼痛	临床2期	保加利亚	Aegera Therapeutics, Inc.	2009-03-01
糖尿病周围神经病变	临床2期	美国	Aegera Therapeutics, Inc.	2009-03-01
糖尿病周围神经病变	临床2期	罗马尼亚	Aegera Therapeutics, Inc.	2009-03-01
糖尿病周围神经病变	临床2期	保加利亚	Aegera Therapeutics, Inc.	2009-03-01
糖尿病周围神经病变	临床2期	加拿大	Aegera Therapeutics, Inc.	2009-03-01